Branded Legacy Advances Development of Air-Driven Intranasal Drug Delivery System

Branded Legacy, Inc. (OTC: BLEG) has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform, marking a critical manufacturing milestone for the company's addiction treatment initiatives. This advancement positions the company to scale production of single-use devices capable of rapid, reliable therapeutic delivery, including its flagship inhaled naloxone program designed to combat opioid overdoses.

The development builds upon the company's September 2025 provisional patent filing and the recent opening of a GMP-compliant facility in Vancouver, strengthening Branded Legacy's manufacturing capacity for pharmaceutical solutions targeting public health emergencies. The timing of this engineering breakthrough comes as communities worldwide continue grappling with opioid-related fatalities, highlighting the urgent need for accessible overdose reversal technologies.

Through its subsidiary BioLegacy Evaluative Group Inc., the company leverages strategic collaborations with leading academic institutions to drive transformative research in harm reduction. The air-driven delivery system represents a technological innovation that could potentially improve administration efficiency compared to traditional methods, particularly in emergency situations where seconds matter.

The scalable production capability enabled by the unitary mold development addresses a critical barrier in overdose prevention: cost-effective manufacturing of reliable medical devices. As described in the company's full press release available at https://ibn.fm/Lgrhz, this manufacturing advancement supports Branded Legacy's mission to deliver high-quality pharmaceutical solutions at accessible price points.

For investors and stakeholders following the company's progress, additional information about Branded Legacy's corporate initiatives and research partnerships can be found at https://BrandedLegacy.com. The engineering milestone demonstrates tangible progress toward commercializing the company's patented drug delivery technology while addressing a pressing public health challenge through innovative medical device development.

The implications of this development extend beyond corporate achievement, potentially impacting healthcare systems, first responders, and communities affected by substance use disorders. As manufacturing capabilities expand, the availability of affordable overdose reversal devices could become more widespread, potentially saving lives in situations where current treatment options remain cost-prohibitive or logistically challenging to administer.